Faculty
Faculty Faculty Publications
Faculty Publications
| Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial | |
|---|---|
| Year of publication | 2019 |
| Title of paper | Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial |
| Author | Higuchi T, Iyo M, Kwon JS, Chou YH, Chen HK, Chen JY, Chen TT, Huang SY, Lee JS, Saeki Y, Tanaka H, Wang TS, Wu BJ, Katoh T, Ishigouoka J |
| Publication in journal | Asia-Pacific Psychiatry |
| Status of publication | accepted |
| Vol | 11(3) |
| Link | https://doi.org/10.1111/appy.12354 201회 연결 |
ObjectiveThe efficacy and safety of lurasidone in schizophrenia has been demonstrated in multiple controlled trials, primarily in US and European populations. The aim of the current study was To evaluate lurasidone for the treatment of schizophrenia among patients in Japan, Korea, and Taiwan. MethodsHospitalized patients (N = 460) with schizophrenia were randomized to 6 weeks of fixed‐dose lurasidone 40 mg/d, lurasidone 80 mg/d, risperidone 4 mg/d, or placebo. Efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression‐Severity (CGI‐S). ResultsNo significant endpoint differences in PANSS total score were found for lurasidone or risperidone vs placebo. Lurasidone was safe and well tolerated, with minimal effects on weight and metabolic parameters. DiscussionThe current study was inconclusive regarding the efficacy of lurasidone in schizophrenia but further confirmed its safety and tolerability. |
|
